Displaying 52 (all) recruiting clinical trials.
-
DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered Recurrent or Progressive Low-Grade Glioma
The purpose of the study is to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with ...Phase
Interventional
-
AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to
The purpose of the study is to investigates how well nivolumab when given together with blinatumomab work compared to blinatumomab alone in treating patients with ...Phase
Interventional
-
A Phase 2 Trial of the Combination of Polatuzumab Vedotin Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
The purpose of the study is to evaluate the activity of a novel triplet combination of rituximab and hyaluronidase human, polatuzumab vedotin, and venetoclax for ...Phase
Interventional
-
A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies
The purpose of the study is to determine if poziotinib helps to treat advanced cancer by targeting treatment of the EGFR or HER2 Mutation-Positive cells ...Phase
Interventional
-
A Phase 2 Open-label Multicenter Cohort Study of ALKS 4230 Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6
The purpose of the study is to evaluate the antitumor activity, safety and tolerability of ALKS 4230 given as monotherapy in patients with unresectable and ...Phase
Interventional
-
PH II study of adjuvant tx with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm) IIA IIB and select IIIA [T3N1 T4N0-1] resected NSCLC and the clearance of (ctDNA)
The purpose of the study is to determine and estimate the percentage of patients with undetectable circulating tumor DNA (ctDNA) after 4 cycles of adjuvant ...Phase
Interventional
-
A Phase 2 Multicenter Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment (CodeBreaK 201)
The purpose of the study is to determine the anti-tumor effect (safety and tolerability) of sotorasib monotherapy in subjects with metastatic non-small cell lung cancer ...Phase
Interventional
-
A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
In stage 1 (early) HER2+ breast cancer, lesser chemotherapy is needed to achieve excellent long-term survival. The current standard therapy is TH (paclitaxel plus trastuzumab ...Phase
Interventional
-
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) [EA6192]
The purpose of the study is to evaluate and determine how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients ...Phase
Interventional
-
A Phase 2 Randomized Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer
Magrolimab is a novel immune checkpoint inhibitor (targeting macrophages in the tumor to support killing of tumor). The purpose of the study is to determine ...Phase
Interventional
